San Diego, USA, October 17, 2016. The German Center for Neurodegenerative Diseases (DZNE), ChemDiv, Inc. and Torrey Pines Investment jointly announced today an agreement initiating a Research and Development collaboration targeting pathways and molecular mechanisms underlying neurological health and disease.
ChemDiv, Torrey Pines Investment and DZNE Announce Research Collaboration
DZNE, the preeminent neurosciences Research Center within Germany’s Helmholtz Association, will work with ChemDiv and Torrey Pines on multiple joint projects to commercialize early stage technologies arising from DZNE’s researchers and physician-scientists. By drawing together ChemDiv’s capacity in chemistry and pharmaceutical drug development with DZNE’s advanced research and clinical capabilities focused on understanding commonalities and differences between various brain pathologies, this partnership aims at developing innovative preventive and therapeutic approaches for treatment of neurodegenerative diseases. Torrey Pines Investment will provide financial and network resources supporting pre-commercial research, as well as early stage venture investments in developing brain medicines up and into the clinical phase, which may be established within the broad collaborative framework.
"I believe that ChemDiv researchers share the same core values and commitment in public private partnering with DZNE scientists. The combination of ChemDiv focused commercial approach to R&D with DZNE’s excellence in fundamental and clinical sciences will yield a rich pipeline of preclinical and clinical research platforms allowing the support of new therapeutic approaches to diagnosis and treatment of neurodegenerative diseases.” ‑ says Ronald Demuth, General Manager ChemDiv.
“Torrey Pines Investment looks forward to participation through nurturing the collaboration’s early stage projects and validating their commercial feasibility for the larger investment community, who could work alongside research and industry and take these opportunities further to success” – added Nikolay Savchuk, Managing Partner, Torrey Pines Investment.
“By collaborating with ChemDiv and Torrey Pines, DZNE opens another pathway to develop and translate scientific innovation into value for patients and society. We are looking forward to work with professional partners with complementary technologies and expertise.” states Pierluigi Nicotera, MD, PhD, Scientific Director and Chairman of the Executive Board of the DZNE.
The DZNE is already implementing translational approaches to research to tap into the expertise of its multidisciplinary partners. The new partnership with ChemDiv and Torrey Pines will provide all parties with an opportunity to nourish each other’s multilateral resources and capabilities.